Rituximab-related viral infections in lymphoma patients

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1307-1312

  Aksoy, Sercan ^a   Harputluoglu, Hakan ^a   Kilickap, Saadettin ^a   Dede, Didem Sener ^a   Dizdar, Omer ^a   Altundag, Kadri ^a   Barista, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Non Hodgkin's lymphoma; Rituximab; Viral infections

Indexed keywords

ANTINEOPLASTIC AGENT; FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CAUSE OF DEATH; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENTEROCOLITIS; FEMALE; HEPATITIS B; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; MONOTHERAPY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SKIN INFECTION; TREATMENT DURATION; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS PNEUMONIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CAUSE OF DEATH; CHICKENPOX; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS B; HUMANS; LIVER FAILURE; LYMPHOMA; MEDLINE; MIDDLE AGED; VIRUS DISEASES;

EID: 34447566087     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701411441     Document Type: Article

References (59)

1. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. and Williams, M. E. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
2. Tsutsumi, Y., Tanaka, J., Kawamura, T., Miura, T., Kanamori, H. and Obara, S. (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol, 83, pp. 58-60.
3. Hamaki, T., Kami, M., Kusumi, E., Ueyama, J., Miyakoshi, S. and Morinaga, S. (2001) Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol, 68, pp. 292-294.
4. Suzan, F., Ammor, M. and Ribrag, V. (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med, 345, p. 1000.
5. Padate, B. P. and Keidan, J. (2006) Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol, 28, pp. 69-71.
6. Huang, C., Slater, B., Rudd, R., Parchuri, N., Hull, R. and Dupuis, M. (2002) First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis, 8, pp. 1367-1371.
7. Goldberg, S. L., Pecora, A. L., Alter, R. S., Kroll, M. S., Rowley, S. D. and Waintraub, S. E. (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood, 99, pp. 1486-1488.
8. Kimby, E. (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev, 31, pp. 456-473.
9. (2000) Center for Disease Control and Prevention, Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant, 6:6, pp. 659-713.
10. Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D. and Budach, V. (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, pp. 176-181.
11. Dervite, I., Hober, D. and Morel, P. (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 344, pp. 68-69.
12. Sarrecchia, C., Cappelli, A. and Aiello, P. (2005) HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother, 11, pp. 189-191.
13. Law, J. K., Ho, J. K., Hoskins, P. J., Erb, S. R., Steinbrecher, U. P. and Yoshida, E. M. (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma, 46, pp. 1085-1089.
14. Tsutsumi, Y., Kawamura, T., Saitoh, S., Yamada, M., Obara, S. and Miura, T. (2004) Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma, 45, pp. 627-629.
15. Soong, Y. L., Lee, K. M., Lui, H. F., Chow, W. C., Tao, M. and Loong, S Li Er (2005) Hepatitis B reactivation in a patient receiving radiolabeled rituximab. Ann Hematol, 84, pp. 61-62.
16. Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L. and LoBuglio, A. F. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 17, pp. 268-276.
17. Ng, H. J. and Lim, L. C. (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol, 80, pp. 549-552.
18. Hernandez, J. A., Diloy, R., Salat, D., Rio, N del, Martinez, X. and Castellvi, J. M. (2003) Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica, 88, p. ECR22.
19. Zell, J. A., Yoon, E. J., Ou, S H Ignatius, Hoefs, J. C. and Chang, J. C. (2005) Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs, 16, pp. 83-85.
20. Westhoff, T. H., Jochimsen, F., Schmittel, A., Stoffler-Meilicke, M., Schafer, J. H. and Zidek, W. (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102, p. 1930.
21. Heider, U., Fleissner, C., Zavrski, I., Jakob, C., Dietzel, T. and Eucker, J. (2004) Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection. Eur J Haematol, 72, pp. 64-66.
22. Dai, M. S., Chao, T. Y., Kao, W. Y., Shyu, R. Y. and Liu, T. M. (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol, 83, pp. 769-774.
23. Ozgonenel, B., Moonka, D. and Savasan, S. (2006) Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol, 81, p. 302.
24. Skrabs, C., Muller, C., Agis, H., Mannhalter, C. and Jager, U. (2002) Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia, 16, pp. 1884-1886.
25. Niscola, P., Principe, M I Del, Maurillo, L., Venditti, A., Buccisano, F. and Piccioni, D. (2005) Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia, 19, pp. 1840-1841.
26. Jaeger, G., Neumeister, P., Brezinschek, R., Hofler, G., Quehenberger, F. and Linkesch, W. (2002) Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: A phase II study. Eur J Haematol, 69, pp. 21-26.
27. Mimidis, K., Tsatalas, C., Margaritis, D., Martinis, G., Spanoudakis, E. and Kotsiou, S. (2002) Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol, 107, pp. 49-51.
28. Law, J. K., Ali, J. A., Harrigan, P. R., Sherlock, C. H., Savage, K. J. and Yoshida, E. M. (2006) Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol, 81, pp. 969-972.
29. Perceau, G., Diris, N., Estines, O., Derancourt, C., Levy, S. and Bernard, P. (2006) Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol, 155, pp. 1053-1056.
30. Sera, T., Hiasa, Y., Michitaka, K., Konishi, I., Matsuura, K. and Tokumoto, Y. (2006) Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med, 45, pp. 721-724.
31. Thomas, D. A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J. and Garcia-Manero, G. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, pp. 1569-1580.
32. Unluturk, U., Aksoy, S., Yonem, O., Bayraktar, Y. and Tekuzman, G. (2006) Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin's lymphoma patient. World J Gastroenterol, 12, pp. 1978-1979.
33. Nomura, K., Kamitsuji, Y., Kono, E., Matsumoto, Y., Yoshida, N. and Konishi, H. (2005) Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma. Scand J Gastroenterol, 40, pp. 604-606.
34. Damaj, G., Charbonnier, A., Bouabdallah, R., Vey, N., Coso, D. and Stoppa, A. M. (2004) Monoclonal antibodies and cytomegalovirus infections. Eur J Haematol, 73, pp. 73-74.
35. Vallet, S., Tempescul, A., Tran, A., Legrand-Quillien, M. C., Narbonne, V. and Berthou, C. (2005) Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann Hematol, 84, pp. 545-547.
36. Byrd, J. C., Peterson, B. L., Morrison, V. A., Park, K., Jacobson, R. and Hoke, E. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, pp. 6-14.
37. Bermudez, A., Marco, F., Conde, E., Mazo, E., Recio, M. and Zubizarreta, A. (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica, 85, pp. 894-895.
38. McIlwaine, L. M., Fitzsimons, E. J. and Soutar, R. L. (2001) Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: An unusual and fatal triad in a patient 13 months post Rituximab and autologous stem cell transplantation. Clin Lab Haematol, 23, pp. 253-254.
39. Quartier, P., Tournilhac, O., Archimbaud, C., Lazaro, L., Chaleteix, C. and Millet, P. (2003) Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis, 36, pp. e47-e49.
40. Archimbaud, C., Bailly, J. L., Chambon, M., Tournilhac, O., Travade, P. and Peigue-Lafeuille, H. (2003) Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000. J Clin Microbiol, 41, pp. 4605-4610.
41. Sharma, V. R., Fleming, D. R. and Slone, S. P. (2000) Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood, 96, pp. 1184-1186.
42. Isobe, Y., Sugimoto, K., Shiraki, Y., Nishitani, M., Koike, K. and Oshimi, K. (2004) Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol, 77, pp. 370-373.
43. Mawhorter, S. D., Sierk, A., Staugaitis, S. M., Avery, R. K., Sobecks, R. and Prayson, R. A. (2005) Fatal West Nile virus infection after rituximab/fludarabine - induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma, 6, pp. 248-250.
44. Matteucci, P., Magni, M., Nicola, M Di, Carlo-Stella, C., Uberti, C. and Gianni, A. M. (2002) Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood, 100, pp. 1104-1105.
45. Scheinpflug, K., Schalk, E., Reschke, K., Franke, A. and Mohren, M. (2006) Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report. Exp Clin Endocrinol Diabetes, 114, pp. 31-34.
46. Sandherr, M., Einsele, H., Hebart, H., Kahl, C., Kern, W. and Kiehl, M. (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol, 17, pp. 1051-1059.
47. Ghielmini, M., Schmitz, S. F., Cogliatti, S., Bertoni, F., Waltzer, U. and Fey, M. F. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol, 23, pp. 705-711.
48. Cheson, B. D. (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol, 13, pp. 2431-2448.
49. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
50. Cornely, O. A., Ullmann, A. J., Heidecke, C. N. and Karthaus, M. (2005) Opportunistic infections (OI) following monoclonal antibody treatment. J Clin Oncol ASCO Ann Meeting Proc, 23, p. 2562.
51. Coiffier, B. (2006) Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of Lamivudine prophylaxis. Cancer Invest, 24, pp. 548-552.
52. Yeo, W., Zee, B., Zhong, S., Chan, P. K., Wong, W. L. and Ho, W. M. (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer, 90, pp. 1306-1311.
53. Rossi, G., Pelizzari, A., Motta, M. and Puoti, M. (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol, 115, pp. 58-62.
54. Yeo, W., Chan, P. K., Ho, W. M., Zee, B., Lam, K. C. and Lei, K. I. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 22, pp. 927-934.
55. Stroffolini, T., Andriani, A., Bibas, M. and Barlattani, A. (2002) Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol, 81, pp. 48-49.
56. Lim, L. L., Wai, C. T., Lee, Y. M., Kong, H. L., Lim, R. and Koay, E. (2002) Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther, 16, pp. 1939-1944.
57. Aksoy, S., Abali, H., Kilickap, S., Erman, M. and Kars, A. (2006) Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol, 28, pp. 211-214.
58. Roccatello, D., Baldovino, S., Rossi, D., Mansouri, M., Naretto, C. and Gennaro, M. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant, 19, pp. 3054-3061.
59. Sansonno, D., De Re, V., Lauletta, G., Tucci, F. A., Boiocchi, M. and Dammacco, F. (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood, 101, pp. 3818-3826.